BioSig Technologies, Inc. (OTCMKTS:BSGM) Files An 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
On October 17, 2019, BioSig Technologies, Inc. (the “Company”) adopted the first amendment to the amended and restated bylaws (the “First Amendment”) that became effective as of October 17, 2019. The board of directors approved the First Amendment on the same date. The First Amendment amends and restates Article III, Section 3.3 of the Company’s amended and restated bylaws in its entirety to set the term of office for the Company’s directors. Specifically, the First Amendment states that each director shall hold office until the next annual meeting of stockholders and until such director’s successor is elected and qualified or until such director’s earlier death, resignation or removal.
The foregoing description of the First Amendment is qualified by reference to the First Amendment, a copy of which is attached hereto as Exhibit 3.1 and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
BioSig Technologies, Inc. Exhibit
EX-3.1 2 ex_160875.htm EXHIBIT 3.1 ex_160875.htm Exhibit 3.1 FIRST AMENDMENT TO AMENDED AND RESTATED BYLAWS OF BIOSIG TECHNOLOGIES,…
To view the full exhibit click here
About BioSig Technologies, Inc. (OTCMKTS:BSGM)
BioSig Technologies, Inc. is a development-stage medical device company. The Company is developing a technology platform to manage noise and artifacts from cardiac recordings during electrophysiology studies and ablation. It is engaged in developing the Precise Uninterrupted Real-time evaluation of Electrograms (PURE) electro-pneumatic (EP) System. PURE EP System is a surface electrocardiogram and intracardiac multichannel recording and analysis system that acquires, processes and displays electrocardiogram and electrograms required during electrophysiology studies and ablation procedures. The Company’s PURE EP System is designed to assist electrophysiologists with real-time evaluations of electrocardiograms and electrograms, and helps in making clinical decisions in real-time. It is also developing signal-processing tools, which will assist electrophysiologists in differentiating true signals from noise and provide guidance in identifying ablation targets within the PURE EP System.
